SCHEMBL1665397

SCHEMBL1665397

CC(C)(C)OC(=O)N1CCN(c2cc(F)c(F)c(C(=O)O)c2F)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 5/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
HTT P42858 1/20 0.42
SMARCA2 P51531 1/20 0.42
SMARCA4 P51532 1/20 0.42
PBRM1 Q86U86 1/20 0.42
CKS1B P61024 1/20 0.41
SKP1 P63208 1/20 0.41
SKP2 Q13309 1/20 0.41
PDK2 Q15119 1/20 0.41
DPP4 P27487 1/20 0.41
TP53 P04637 1/20 0.40
THRB P10828 1/20 0.40
KIT P10721 1/20 0.40
BACE1 P56817 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29471910 0.85 MAPT (0.46) GPR119SMN1; SMN2ALDH1A1LMNAMAPT
SCHEMBL1663232 0.85 MAPT (0.46) GPR119SMN1; SMN2ALDH1A1LMNAMAPT
SCHEMBL27183715 0.82 MAPT (0.51) GPR119SMN1; SMN2ALDH1A1LMNAMAPT
SCHEMBL1665283 0.81 GPR119 (0.48) GPR119ALDH1A1LMNAMAPTHTT
SCHEMBL20046895 0.81 SMN1; SMN2 (0.48) GPR119SMN1; SMN2ALDH1A1LMNAMAPT
SCHEMBL20139942 0.81 GPR119 (0.45) GPR119SMN1; SMN2ALDH1A1LMNAMAPT
SCHEMBL710108 0.81 ALDH1A1 (0.51) GPR119SMN1; SMN2ALDH1A1LMNAMAPT
SCHEMBL1663320 0.80 GPR119 (0.47) GPR119ALDH1A1LMNAMAPTHTT
SCHEMBL31211209 0.80 GPR119 (0.41) GPR119SMN1; SMN2ALDH1A1LMNAMAPT
SCHEMBL20140111 0.80 MAPT (0.54) GPR119SMN1; SMN2ALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242987-B2 Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors CELLZOME LIMITED (GB) 2016-01-26 US disclosed
US-20120252779-A1 HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS CELLZOME LIMITED (GB) 2012-10-04 US disclosed
CN-102666545-A Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors CELLZOME LTD 2012-09-12 CN disclosed
EP-2491039-A1 HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS Cellzome Limited (GB) 2012-08-29 EP disclosed
WO-2011048082-A1 HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS CELLZOME LIMITED (GB) 2011-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120252779-A1 HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS JAK1, JAK3, JAK2 GPR119 3906/4885SMN1; SMN2 4699/4885ALDH1A1 2233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.